Defeat Duchenne Canada, the country's leading funder of Duchenne muscular dystrophy (DMD) research, is set to begin accepting innovative research proposals as of March 31, 2025. They are seeking ...

From April 1, 2025, the higher TDS rate for non-filers (as per Section 206AB) will not apply under Section 194-IA ...

Trial achieved key objectives for safety, tolerability, pharmacokinetics and pharmacodynamicsClinical data from this trial, ...

New research led by the University of Portsmouth has revealed how Duchenne muscular dystrophy (DMD), best known for causing ...

Sarepta Therapeutics announced that a patient with Duchenne muscular dystrophy who received Elevidys (delandistrogene moxeparvovec-rokl) died following treatment.

New research led by the University of Portsmouth has revealed how Duchenne muscular dystrophy (DMD), best known for causing ...

A Reed City family is partnering with the Jett Foundation to help raise money for a wheelchair-accessible van.14-year-old ...

WVE-N531 demonstrated statistically significant improvements in muscle biopsy measures and functional measures in patients ...

Wave Life Sciences Ltd. shares promising updates on AATD & DMD treatments. Click here for my updated look at WVE stock ...

Long-term treatment with Duvyzat (givinostat) may help delay the loss of walking ability and lessen the decline in lung ...

Cambridge, USA-based RNS specialist Wave Life Sciences (Nasdaq: WVE) has announced positive data from the Phase II FORWARD-53 trial of WVE-N531, which is an exon skipping oligonucleotide being ...

The patient died of acute liver failure; the maker of the gene therapy noted that the patient also had a recent ...